BACKGROUND: Alveolar macrophages (AM) are the major population in bronchoalveolar lavage (BAL) cells; we assessed their role in human lung allograft recipients by correlating the expression of adhesion molecules and inflammatory cytokines with clinical outcome of allograft. METHODS: We obtained BAL samples from patients and enriched them for AM in plastic petri dish for 2 hours at 37 degrees C in 5% CO(2). Expression of intercellular adhesion molecule-1 (ICAM-1, CD54), platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31), and CD11c was assessed by flow cytometry using monoclonal antibodies. We assessed cytokine profile using Multi-Probe RNase protection assay. RESULTS: Alveolar macrophages that express CD11c, CD31 and CD54 were increased in patients with either rejection or infection compared with those without rejection and infection. The difference in the percentage of AM expressing CD11c and CD31 between the rejection group and patients without rejection and infection group was statistically significant (CD11c, p < 0.01; CD31, p < 0.03). Interleukin (IL)-1 alpha, IL-1 beta, IL-1 receptor antagonist (IL-1Ra), and IL-6 expression was higher in the rejection group than in patients without rejection. Five out of 9 patients in the rejection group expressed high levels of IL-15 and tumor necrosis factor-alpha compared with patients without rejection and infection. The increased number of AM expressing adhesion molecules and elevated expression of cytokines observed during acute rejection declined to basal levels after successful treatment and resolution of rejection. This study demonstrates that lung allograft rejection is associated with increased expression of adhesion molecules and inflammatory cytokines by AM, which could facilitate mononuclear cell adhesion and extravasation contributing to the allograft injury in lung transplant recipients.
BACKGROUND: Alveolar macrophages (AM) are the major population in bronchoalveolar lavage (BAL) cells; we assessed their role in human lung allograft recipients by correlating the expression of adhesion molecules and inflammatory cytokines with clinical outcome of allograft. METHODS: We obtained BAL samples from patients and enriched them for AM in plastic petri dish for 2 hours at 37 degrees C in 5% CO(2). Expression of intercellular adhesion molecule-1 (ICAM-1, CD54), platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31), and CD11c was assessed by flow cytometry using monoclonal antibodies. We assessed cytokine profile using Multi-Probe RNase protection assay. RESULTS: Alveolar macrophages that express CD11c, CD31 and CD54 were increased in patients with either rejection or infection compared with those without rejection and infection. The difference in the percentage of AM expressing CD11c and CD31 between the rejection group and patients without rejection and infection group was statistically significant (CD11c, p < 0.01; CD31, p < 0.03). Interleukin (IL)-1 alpha, IL-1 beta, IL-1 receptor antagonist (IL-1Ra), and IL-6 expression was higher in the rejection group than in patients without rejection. Five out of 9 patients in the rejection group expressed high levels of IL-15 and tumor necrosis factor-alpha compared with patients without rejection and infection. The increased number of AM expressing adhesion molecules and elevated expression of cytokines observed during acute rejection declined to basal levels after successful treatment and resolution of rejection. This study demonstrates that lung allograft rejection is associated with increased expression of adhesion molecules and inflammatory cytokines by AM, which could facilitate mononuclear cell adhesion and extravasation contributing to the allograft injury in lung transplant recipients.
Authors: Shahid Husain; Mariangela R Resende; Nimerta Rajwans; Ricardo Zamel; Joseph M Pilewski; Maria M Crespo; Lianne G Singer; Kenneth R McCurry; Jay K Kolls; Shaf Keshavjee; W Conrad Liles Journal: Transplantation Date: 2014-01-15 Impact factor: 4.939
Authors: Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn Journal: Semin Immunopathol Date: 2011-01-27 Impact factor: 9.623
Authors: Natalie M Walker; Linda N Badri; Anish Wadhwa; Scott Wettlaufer; Marc Peters-Golden; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: J Zhang; H K Takahashi; K Liu; H Wake; R Liu; H Sadamori; H Matsuda; T Yagi; T Yoshino; S Mori; M Nishibori Journal: Br J Pharmacol Date: 2010-07 Impact factor: 8.739
Authors: Rong Chen; Tara K Sigdel; Li Li; Neeraja Kambham; Joel T Dudley; Szu-Chuan Hsieh; R Bryan Klassen; Amery Chen; Tuyen Caohuu; Alexander A Morgan; Hannah A Valantine; Kiran K Khush; Minnie M Sarwal; Atul J Butte Journal: PLoS Comput Biol Date: 2010-09-23 Impact factor: 4.475
Authors: Joe L Hsu; Olga V Manouvakhova; Karl V Clemons; Mohammed Inayathullah; Allen B Tu; Raymond A Sobel; Amy Tian; Hasan Nazik; Venkata R Pothineni; Shravani Pasupneti; Xinguo Jiang; Gundeep S Dhillon; Harmeet Bedi; Jayakumar Rajadas; Hubertus Haas; Laure Aurelian; David A Stevens; Mark R Nicolls Journal: Sci Transl Med Date: 2018-02-21 Impact factor: 17.956